Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)’ Relacorilant in ovarian cancer on an Analyst/Industry conference call to be held on July 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
- Corcept Therapeutics Completes Key Study on Drug Interaction
- Corcept Therapeutics Explores Hypercortisolism in Hypertension: A Market Game Changer?
- Corcept Therapeutics’ Phase 2 Study Update: New Hope for Ovarian Cancer Treatment
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Resistant Hypertension